Cladribine treatment outcomes of hairy cell leukemia

Basit Öğe Kaydı
dc.contributor.authorAltintaş A.
dc.contributor.authorAyyildiz O.
dc.contributor.authorAtay A.E.
dc.contributor.authorÇil T.
dc.contributor.authorMüftüoğlu E.
dc.date.accessioned2024-04-24T18:43:39Z
dc.date.available2024-04-24T18:43:39Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractHairy cell leukemia is a rare, clonal, chronic B cell lenfoproliferative disease characterized by splenomegaly and pancytopenia. Purine analogues are first-line choice of therapy. Although effectivity of treatment is established, relapses may occur. In this state, remission may achieved by a new cycle of 2-CdA or alternative modalities. In this report, we represented the results of our patients with HCL that were treated with 2-CdA and followed up in our center.en_US
dc.identifier.endpage70en_US
dc.identifier.issn1306-133X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-33745745839en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage67en_US
dc.identifier.urihttps://hdl.handle.net/11468/24257
dc.identifier.volume16en_US
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.relation.ispartofUHOD - Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCladribineen_US
dc.subjectHairy Cell Leukemiaen_US
dc.titleCladribine treatment outcomes of hairy cell leukemiaen_US
dc.title.alternativeHairy cell lösemi olgularimizda cladribine tedavi sonuçlarien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu